Requires health insurance policies to cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers.

New York Assembly Bill A06475 mandates that health insurance policies must cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers. This coverage applies when recommended by a doctor, a board-certified geneticist, or a board-certified genetic counselor. It also extends to family members of patients diagnosed with these cancers. The bill ensures that genetic results cannot be used against family members for insurance coverage purposes and exempts these costs from annual deductibles and coinsurance, placing the full burden on the insurer.

Requires health insurance policies to cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers.

New York Assembly Bill A06475 mandates that health insurance policies must cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers. This coverage applies when recommended by a doctor, a board-certified geneticist, or a board-certified genetic counselor. It also extends to family members of patients diagnosed with these cancers. The bill ensures that genetic results cannot be used against family members for insurance coverage purposes and exempts these costs from annual deductibles and coinsurance, placing the full burden on the insurer.